SCHEMBL289800

SCHEMBL289800

O=c1[nH]c2cc(Br)ccc2s1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 1/20 0.61
PDE3B Q13370 3/20 0.53
PDE3A Q14432 3/20 0.53
METAP2 P50579 1/20 0.41
PGR P06401 2/20 0.40
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
DAPK3 O43293 1/20 0.37
JAK2 O60674 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
PAK4 O96013 1/20 0.37
ABL1 P00519 1/20 0.37
NTRK1 P04629 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37
MET P08581 1/20 0.37
PDGFRB P09619 1/20 0.37
PIM1 P11309 1/20 0.37
FGFR1 P11362 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29477415 1.00 CMA1 (0.61) CMA1PDE3BPDE3AMETAP2PGR
SCHEMBL489133 0.86 PDE3B (0.55) CMA1PDE3BPDE3AMETAP2PGR
SCHEMBL29895649 0.86 PDE3B (0.55) CMA1PDE3BPDE3AMETAP2PGR
SCHEMBL6238353 0.77 PIM1 (0.44) CMA1METAP2CHEK1AURKADAPK3
SCHEMBL30537992 0.76 CMA1 (1.00) CMA1PDE3BPDE3APGRMEN1
SCHEMBL30613119 0.76 CMA1 (0.61) CMA1PDE3BPDE3APGRPRKD3
SCHEMBL8286761 0.76 CMA1 (0.61) CMA1PDE3BPDE3APGRTP53
SCHEMBL30534236 0.76 CMA1 (0.61) CMA1PDE3BPDE3APGRLMNA
SCHEMBL3224706 0.76 CMA1 (0.61) CMA1PDE3BPDE3APGRLMNA
SCHEMBL9286435 0.76 CMA1 (0.61) CMA1PDE3BPDE3APGRRPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630516-B2 Compounds NRG THERAPEUTICS LTD. (GB) 2026-05-19 US disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
EP-4208442-B1 MPTP INHIBITORS NRG THERAPEUTICS LTD (GB) 2025-10-22 EP disclosed
US-20250179028-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2025-06-05 US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 US disclosed
US-12264154-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-04-01 US disclosed
EP-4486721-A1 ACRYLAMIDE COMPOUNDS NRG Therapeutics LTD (GB) 2025-01-08 EP disclosed
US-20240294482-A1 METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR INNER MONGOLIA UNIVERSITY OF TECHNOLOGY (CN) 2024-09-05 US disclosed
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-6794373-B2 ADMINISTERING TO A FEMALE OF CHILD BEARING AGE OVER A PERIOD OF 28 CONSECUTIVE DAYS A FIRST PHASE OF FROM 18 TO 21 DAILY DOSAGE UNITS OF A PROGESTATIONAL AGENT, AND A SECOND PHASE OF FROM 1 TO 7 DAILY DOSAGE UNITS OF AN ANTIPROGESTIN AGENT WYETH 2004-09-21 US disclosed
CN-1152020-C Benzimidazolrone and analogues, and the use as ligand of progesterone �Ʒ� 2004-06-02 CN disclosed
US-20020151531-A1 Contraceptive methods using benzimidazolones LIGAND PHARMACEUTICALS INCORPORATED 2002-10-17 US disclosed
US-20020115853-A1 Benzimidazolones and analogues WYETH 2002-08-22 US disclosed
US-6423699-B1 CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION 2002-07-23 US disclosed
CN-1349511-A Benzimidazolrone and analogues, and the use as ligand of progesterone AMERICAN HOME PROD (US) 2002-05-15 CN disclosed
CN-1349411-A Compositions containing benzimidazolones and progestogens AMERICAN HOME PROD (US) 2002-05-15 CN disclosed
US-6380235-B1 USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY AMERICAN HOME PRODUCTS CORPORATION 2002-04-30 US disclosed
EP-1173213-A1 COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS American Home Products Corporation (US) 2002-01-23 EP disclosed
WO-2000066168-A1 COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630516-B2 Compounds CYP4B1, CYP1B1, NR4A1 CMA1 2165/4885PDE3B 2067/4885PDE3A 3080/4885
US-20240294482-A1 METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR TST, CBR3, SMOX CMA1 810/4885PDE3B 4085/4885PDE3A 4059/4885
US-20250179028-A1 ACRYLAMIDE COMPOUNDS ACR, CCNI, FANCI CMA1 3861/4885PDE3B 3128/4885PDE3A 3172/4885
US-20240279219-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 CMA1 322/4885PDE3B 249/4885PDE3A 306/4885
US-12264154-B2 Compounds and methods of use F12, C1R, ABCG2 CMA1 322/4885PDE3B 249/4885PDE3A 306/4885
US-20020151531-A1 Contraceptive methods using benzimidazolones PGR, GNRHR, NR4A1 CMA1 2503/4885PDE3B 1880/4885PDE3A 2278/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 CMA1 322/4885PDE3B 249/4885PDE3A 306/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 CMA1 322/4885PDE3B 249/4885PDE3A 306/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 CMA1 1997/4885PDE3B 2434/4885PDE3A 2376/4885
US-20020115853-A1 Benzimidazolones and analogues PGR, NR5A1, NR3C2 CMA1 2173/4885PDE3B 799/4885PDE3A 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.